• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by NuVasive Inc.

    2/13/23 3:58:05 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care
    Get the next $NUVA alert in real time by email
    SC 13G 1 tfl13gnuvasive.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.      )*



    NuVasive, Inc.
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     
     670704105
      (CUSIP Number)
     
     December 31, 2022
     (Date of Event Which Requires Filing of this Statement)
     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]
    Rule 13d-1(b)

    [   ]
    Rule 13d-1(c)

    [   ]
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     

    CUSIP No. 670704105
     
    1
    NAMES OF REPORTING PERSONS.
     
    Thrivent Financial for Lutherans
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     
    (a)     ☐
    (b)     ☐
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    Wisconsin
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER

    65,149(1)
    6
    SHARED VOTING POWER
     
    3,154,365(2)
    7
    SOLE DISPOSITIVE POWER

    65,149(1)
    8
    SHARED DISPOSITIVE POWER
     
    3,154,365(2)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,219,514(1), (2)
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.18%(3)
    12
    TYPE OF REPORTING PERSON (See Instructions)

    IC, IA
     
    (1)
    Represents shares held by Thrivent Financial for Lutherans in its general account and shares held in the Thrivent Defined Benefit Plan Trust for which Thrivent Financial for Lutherans serves as investment adviser.
    (2)
    Represents 1,157,586 shares held by registered investment companies for which Thrivent Financial for Lutherans serves as investment adviser, and 1,996,779 shares held by registered investment companies for which Thrivent Asset Management, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Thrivent Financial for Lutherans, serves as investment adviser.
    (3)
    The percentage calculations used herein are based on the statement in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, as filed with the Securities and Exchange Commission on November 9, 2022, that were 52,133,961 shares of Nuvasive, Inc. Common Stock outstanding at November 7, 2022.

    Item 1.
     
    (a) Name of Issuer:
     
     
     
    NuVasive, Inc.
     
     
     
     
    (b) Address of Issuer’s Principal Executive Offices:
     
     
       
    7475 Lusk Blvd
    San Diego, CA 92121
          
    Item 2.   (a) Name of Person Filing:
          
        Thrivent Financial for Lutherans
         
        (b) Address of Principal Business Office or, if None, Residence:
         
       
    901 Marquette Avenue, Suite 2500
    Minneapolis, MN 55402
          
       
    (c) Citizenship:
           
        Thrivent Financial for Lutherans is a Wisconsin fraternal benefit society.
          
        (d) Title of Class of Securities:
         
        Common Stock
         
        (e) CUSIP Number:
         
       
    670704105
              
    Item 3.
    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
            
     
    (a)
    ☐
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
    (b)
    ☐
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
    (c)
    ☒
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
    (d)
    ☐
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
    (e)
    ☒
    Investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ☐
    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) ☐
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) ☐
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j) ☐
    Group, in accordance with § 240.13d-1(b)(1)(ii)(J).
     

     
    Item 4.
    Ownership.

    (a)
    Amount beneficially owned:

    3,219,514 (1), (2)

    (b)
    Percent of Class:

    6.18% (3)

    (c)
    Number of shares as to which the person has:

    (i)
    Sole power to vote or to direct the vote:  65,149(1)

    (ii)
    Shared power to vote or to direct the vote:  3,154,365 (2)

    (iii)
    Sole power to dispose or to direct the disposition of:  65,149 (1)

    (iv)
    Shared power to dispose or to direct the disposition of:  3,154,365 (2)

    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group.

    Not applicable.

    Item 9.
    Notice of Dissolution of Group.

    Not applicable.
    _____________________________________
    (1)
    See Note 1 on the cover page.  Thrivent Financial for Lutherans disclaims beneficial ownership of the 24,452 shares held in the Thrivent Defined Benefit Plan Trust.
    (2)
    See Note 2 on the cover page.  Thrivent Financial for Lutherans and Thrivent Asset Management, LLC disclaim beneficial ownership of these shares.
    (3)
    The percentage calculations used herein are based on the statement in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 as filed with the Securities and Exchange Commission on November 9, 2022, that there were 52,133,961 shares of NuVasive, Inc. Common Stock outstanding as of November 7, 2022.


    Item 10.
    Certifications.
     
     
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


    Dated: February 13, 2023

     
    Thrivent Financial for Lutherans
     
     
     
    By:   /s/ David S. Royal                                            
    Name: David S. Royal
    Title: Chief Financial Officer





    Get the next $NUVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUVA

    DatePrice TargetRatingAnalyst
    2/10/2023$57.72Overweight → Equal Weight
    Wells Fargo
    2/10/2023$63.00 → $52.00Buy → Neutral
    Citigroup
    2/10/2023$51.00 → $52.50Buy → Hold
    Truist
    1/6/2023Buy → Hold
    Needham
    10/18/2022$53.00Overweight
    Barclays
    10/12/2022$45.00Hold
    Jefferies
    4/13/2022$60.00 → $65.00Buy
    Truist
    3/28/2022$58.00Overweight
    Wells Fargo
    More analyst ratings

    $NUVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NuVasive to Participate as Double Diamond Sponsor at Scoliosis Research Society Annual Meeting

      SAN DIEGO, Aug. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 58th Annual Meeting held September 6-9, 2023, in Seattle.  "We partner with esteemed societies like SRS because of our shared dedication to clinical research, education, and thought leadership around advancing patient care, especi

      8/30/23 7:00:00 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • Goosehead Insurance and Jackson Financial Set to Join S&P SmallCap 600

      NEW YORK, Aug. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1: Goosehead Insurance Inc. (NASD: GSHD) will replace NuVasive Inc. (NASD: NUVA) in the S&P SmallCap 600. S&P MidCap 400 constituent Globus Medical Inc. (NYSE:GMED) is acquiring NuVasive in a deal expected to close soon pending final conditions.Jackson Financial Inc. (NYSE:JXN) will replace NexTier Oilfield Solutions Inc. (NYSE:NEX) in the S&P SmallCap 600. S&P SmallCap 600 constituent Patterson-UTI Energy Inc. (NASD: PTEN) is acquiring NexTier Oilfield Solutions in a deal expected to close soon pending final cond

      8/28/23 5:41:00 PM ET
      $GMED
      $GSHD
      $JXN
      $NEX
      Medical/Dental Instruments
      Health Care
      Specialty Insurers
      Finance
    • NuVasive Announces Second Quarter 2023 Financial Results

      –U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi

      8/2/23 4:05:00 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Wolterman Dan

      4 - NUVASIVE INC (0001142596) (Issuer)

      9/5/23 5:06:55 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Raimundo Amy Belt

      4 - NUVASIVE INC (0001142596) (Issuer)

      9/5/23 5:04:52 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Norwalk Leslie V returned 3,095 shares to the company, closing all direct ownership in the company

      4 - NUVASIVE INC (0001142596) (Issuer)

      9/5/23 4:55:04 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Financials

    Live finance-specific insights

    See more
    • NuVasive Announces Second Quarter 2023 Financial Results

      –U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi

      8/2/23 4:05:00 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • NuVasive Announces Conference Call and Webcast of Second Quarter 2023 Results

      SAN DIEGO, July 24, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, August 2, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the second quarter of 2023. The dial-in numbers are 1-877-407-9039 for domestic calle

      7/24/23 7:00:00 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • NuVasive Announces First Quarter 2023 Financial Results

      –Continued above-market worldwide net sales growth of 5.8% as reported and 7.7% on a constant currency basis––U.S. cervical delivers sixth consecutive quarter of greater than 20% growth, driven by C360 and the Simplify Cervical Disc– SAN DIEGO, May 10, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Highlights Net sales were $307.7 million, a

      5/10/23 4:05:00 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)

      SC 13G/A - NUVASIVE INC (0001142596) (Subject)

      9/11/23 1:33:44 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by NuVasive Inc.

      SC 13G - NUVASIVE INC (0001142596) (Subject)

      2/13/23 3:58:05 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)

      SC 13G/A - NUVASIVE INC (0001142596) (Subject)

      12/6/22 10:35:04 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Leadership Updates

    Live Leadership Updates

    See more
    • BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

      SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

      9/7/22 8:30:00 AM ET
      $AFIB
      $AVGR
      $HYPR
      $NUVA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Blue Spark Technologies Announces Appointment of John DeFord, Ph.D. to its Board of Directors

      The new board member will provide extensive expertise to expand the TempTraq® remote patient monitoring platform Blue Spark Technologies Inc., a leader in wearable remote patient monitoring solutions, announced today the appointment of John DeFord, Ph.D. to its board of directors. Dr. DeFord's appointment, effective April 13th, 2022, brings the number of board members to five. "This is really an inflection point for the company and it's an exciting time to be involved. I look forward to helping mold the future of their technology," said Dr. DeFord. "I'm particularly excited to see the technology come together that will make an impact in patient's lives." "We are proud to welcome John to

      5/2/22 7:00:00 AM ET
      $NDSN
      $NUVA
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care
    • NuVasive Appoints Andrew C. Morton as Chief Human Resources Officer

      SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Andrew (Drew) C. Morton as senior vice president and chief human resources officer (CHRO) effective February 7, 2022. Mr. Morton brings more than 25 years of experience in human resources, talent development, employee experience, and diversity and inclusion. As CHRO, Mr. Morton will oversee all human resources aspects of the Company

      1/31/22 4:10:00 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    SEC Filings

    See more
    • SEC Form 15-12G filed by NuVasive Inc.

      15-12G - NUVASIVE INC (0001142596) (Filer)

      9/11/23 4:46:57 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by NuVasive Inc.

      EFFECT - NUVASIVE INC (0001142596) (Filer)

      9/8/23 12:15:09 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by NuVasive Inc.

      EFFECT - NUVASIVE INC (0001142596) (Filer)

      9/8/23 12:15:14 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NuVasive downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded NuVasive from Overweight to Equal Weight and set a new price target of $57.72

      2/10/23 8:01:18 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • NuVasive downgraded by Citigroup with a new price target

      Citigroup downgraded NuVasive from Buy to Neutral and set a new price target of $52.00 from $63.00 previously

      2/10/23 7:45:41 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • NuVasive downgraded by Truist with a new price target

      Truist downgraded NuVasive from Buy to Hold and set a new price target of $52.50 from $51.00 previously

      2/10/23 7:45:03 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care